Abstract Types

CRA
Clinical Review Abstract

LBA
Late-Breaking Abstract

TPS
Trials in Progress Abstract

e
Abstracts selected for publication but not presentation at the Annual Meeting

^
Abstracts granted an exception in accordance with ASCO's Conflict of Interest Policy



Breast cancer mortality among users of cholesterol-lowering drugs.

Sub-category:
Cancer Prevention

Category:
Cancer Prevention/Epidemiology

Meeting:
2013 ASCO Annual Meeting

Abstract No:
1514

Citation:
J Clin Oncol 31, 2013 (suppl; abstr 1514)

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Teemu Johannes Murtola, Kala Visvanathan, Miia Artama, Harri Vainio, Eero Pukkala; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Johns Hopkins Bloomberg School of Public Health and Johns Hopkins Sidney Kimmel Comprehensive Cancer, Baltimore, MD; The Finnish Cancer Registry, Helsinki, Finland; Finnish Institute of Occupational Health, Helsinki, Finland

Abstract Disclosures


Abstract:

Background: Breast cancer is a common malignancy and cause of cancer death. Recent studies have suggested that statins, an established cholesterol-lowering drug group used in the prevention of cardiovascular mortality, could have beneficial effects against recurrence and progression of breast cancer. We evaluated breast cancer-specific mortality among users of statins and other cholesterol-lowering drugs (fibrates and bile-acid binding resins) in a cohort of breast cancer patients. Methods: Our study cohort included all newly diagnosed breast cancer patients in Finland during 1995-2003 (31,236 cases), identified from the Finnish Cancer Registry. Information on cholesterol-lowering medication use was obtained from a national prescription database.We used Cox proportional hazards regression method to estimate mortality among medication users. Results: A total of 4,169 participants had used statins, while 313 had used fibrates or resins. Despite similar median age, tumor and treatment characteristics, only statin use was associated with decreased breast cancer mortality (participants with localized tumors: HR 0.33, 95% CI 0.24-0.42; metastatic tumors: HR 0.52, 95% CI 0.31-0.86). Fibrate and resin use were associated with increased overall mortality (HR 1.70, 95% CI 0.96-2.99 for participants with localized disease, HR 2.65, 95% CI 1.18-5.96 for participants with metastatic disease). Conclusions: Decreased breast cancer mortality among users of statins, but not other cholesterol-lowering drugs despite similar population characteristics suggests that this drug group may have benefit in prevention of cancer progression. Clinical trials testing statins’ efficacy in breast cancer patients are warranted.

 

  Other Abstracts in this Sub-Category:

 

1. Effect of visual inspection with acetic acid (VIA) screening by primary health workers on cervical cancer mortality: A cluster randomized controlled trial in Mumbai, India.

Meeting: 2013 ASCO Annual Meeting Abstract No: 2 First Author: S. S. Shastri
Category: Cancer Prevention/Epidemiology - Cancer Prevention

 

2. Efficacy of risk-reducing mastectomy (RRM) on overall survival (OS) in BRCA1/2-associated breast cancer (BC) patients.

Meeting: 2013 ASCO Annual Meeting Abstract No: 1502 First Author: B. A. Heemskerk-Gerritsen
Category: Cancer Prevention/Epidemiology - Cancer Prevention

 

3. Breast cancer surveillance in high-risk women with magnetic resonance imaging every 6 months.

Meeting: 2013 ASCO Annual Meeting Abstract No: 1506 First Author: R. S. Guindalini
Category: Cancer Prevention/Epidemiology - Cancer Prevention

 

More...